pharma news today obesity drugs glp-1 Roche was among the first pharmaceutical companies to research in the glucagon-like peptide-1 (GLP-1) class but abandoned the field after late-stage flops just before the latest boom began.⁠ ⁠ Having GLP-1s: Weight loss drugs pose

A FedRAMPapproved cloud is not required, but cybersecurity best practices and modular design are essential

Saxenda is approved for weight management in adults and adolescents with obesity (BMI 30) or overweight (BMI 27) with conditions like high cholesterol, high blood pressure, or type 2 diabetes

However, the serum levels of total triglycerides and cholesterol were significantly increased in mice treated with either dose of L-carnitine, with increases over 100% (Fig

Reported or emerging application areas include joint disorders [33, 34], psychotic and neurocognitive conditions [35], cardiovascular disease [36], and gastrointestinal disorders [37,38,39]